Fresenius SE & Co. KGaA

Earnings Release • Apr 30, 2013

Factsheet Q1 / 2013

COMPANY PROFILE

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. Approximately 170,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	Q1/2013	Change	2012	Change
Sales and Earnings
Sales	4,890	11%	19,290	18%
EBIT 1	696	5%	3,075	20%
Net income (before special items) 2	224	12%	938	22%
Earnings per ord. share in € (before special items) 2	1.26	2%	5.42	15%
Balance sheet and cash fl ow
Total assets	31,311	2%	30,664	17%
Non-current assets	23,044	2%	22,551	18%
Equity 3	13,298	4%	12,758	21%
Equity ratio 3	43%	--	42%	--
Net debt / EBITDA 4	2.57	--	2.56	--
Investments 5	258	-88%	4,179	74%
Operating cash fl ow	444	-17%	2,438	44%
Operating cash fl ow in % of sales	9.1%	--	12.6%	--
Profi tability
EBIT margin 1	14.2%	--	15.9%	--
Return on equity after taxes (ROE) 2	12.1%	--	12.3%	--
Return on operating assets (ROOA) 1	10.9%	--	11.0%	--
Return on invested capital (ROIC) 1	8.8%	--	9.0%	--
Employees (Mar 31 / Dec 31)	171,764	7%	169,324	13%

2013 adjusted for one-time integration costs of Fenwal Holdings, Inc. of €7 million. 2012 adjusted for one-time costs related to the offer to the shareholders of RHÖNKLINIKUM AG as well as for other one-time costs at Fresenius Medical Care.

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA. 2013 adjusted for one-time integration costs of Fenwal of €5 million after tax. 2012 adjusted for a non-taxable investment gain and other one-time costs at Fresenius Medical Care as well as for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.

3 Including noncontrolling interest

4 2013 and 2012 before special items 5 Investments in property, plant and equipment and intangible assets, acquisitions

SALES BY REGION

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

31% 1	100%	100%	77%
Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed
1 As of March 31, 2013

BUSINESS SEGMENTS

€ in millions		Q1 /2013	Change	2012	Change
	Umsatz EBIT	2.623 374	6 % -3 %	10.741 1.813	19 % 22 %
	Umsatz EBIT	1.260 237	15 % 10 %	4.539 934	15 % 16 %
	Umsatz EBIT	841 87	18 % 28 %	3.200 322	20 % 19 %
	Umsatz EBIT	184 5	23 % 0 %	846 51	15 % 16 %

• ▶ Fresenius Medical Care is the world's leading provider of services and products for patients with chronic kidney failure. As of March 31, 2013, Fresenius Medical Care was treating 261,648 patients in 3,180 dialysis clinics.
• ▶ Fresenius Kabi offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products in Germany.
• ▶ Fresenius Helios is one of the largest private hospital operators in Germany. HELIOS owns 74 hospitals, including 6 maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin and Wuppertal. HELIOS treats more than 2.9 million patients per year, thereof more than 780,000 inpatients, and operates more than 23,000 beds.
• ▶ Fresenius Vamed offers engineering and services for hospitals and other health care facilities.

Q1 / 2013: €4.9 billion

SALES BY BUSINESS SEGMENT

FRESENIUS SHARE / ADR

	Ordinary share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of ordinary shares (March 31, 2013)	178,271,131
Market capitalization (March 31, 2013)	€17.2 billion

Issuer	ISIN	Volume in million	Coupon	Matu rity
Fresenius Finance B. V.	XS0759200321	€500	4.25%	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875%	2020
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015

Bonds of Fresenius Medical Care can be found under www.fmc-ag.com\Credit Relations.

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX DAX Fresenius ordinary share

SHARE PERFORMANCE 1

1 month	+ 2.3 %
4 th quarter	+ 10.6 %
1 year	+ 25.2 %
5 years	+ 78.7 %
10 years	+ 615.0 %

Effective date / closing price: March 31, 2013

Targets 2013

Dates

DEVELOPMENT ORDINARY SHARE DIVIDENDS IN €

1 Proposal

90

95

100

105

110

115

This release contains forward-looking statements that are subject to various risks and uncertainties. CONTACT Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fl uctuations, uncertainties in litigation or investigative proceedings, and the availability of fi nancing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Offi ce: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE

Registered Offi ce: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler Chairman of the Supervisory Board: Dr. Gerd Krick

GROUP OUTLOOK 2013

Sales growth (in constant currency)	7% – 10%
Net income 1 , growth (in constant currency)	7% – 12%
Capital expenditure	~ 5% of group sales

1 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 adjusted for one-time integration costs of Fenwal, Inc. (~ € 50 million pre tax); 2012 adjusted for an investment gain and other one-time costs at Fresenius Medical Care as well as for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.

For the outlook of the business segments please see the Investor News of April 30, 2013.

FINANCIAL CALENDAR

Annual General Meeting, Frankfurt / Main	May 17, 2013
Payment of dividend 1	May 20, 2013
Report on 1st half 2013	July 30, 2013
Report on 1st – 3rd quarter 2013	November 5, 2013
1 Subject to prior approval by the Annual General Meeting

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H. e-mail: ir-fre@fresenius.com Internet: www.fresenius.com

Birgit Grund

Senior Vice President Investor Relations Telephone: ++49 61 72 6 08-24 85 Telefax: ++49 61 72 6 08-24 88

Leslie Iltgen Vice President Investor Relations Telephone: ++49 61 72 6 08-44 78 Telefax: ++49 61 72 6 08-24 88